Galapagos Gets €17M Up Front From Janssen In RA Partnership
Galapagos NV's drug discovery programs got a major shot in the arm with a multitarget, potential multimillion-dollar rheumatoid arthritis deal with Johnson & Johnson unit Janssen Pharmaceutica NV.
At its peak, the collaboration could bring Galapagos as much as €1 billion (US$1.43 billion) in up-front payments, license fees and milestones, and could involve as many as 15 to 19 targets.
Suite: 1100 | Atlanta, Georgia 30346, USA
In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-770-810-3144
In the U.S. and Canada: 1-800-336-4474
Outside the U.S.: 1-215-386-0100
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter